Cargando…
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
INTRODUCTION: Atopic dermatitis (AD) can affect multiple body regions and is especially burdensome when involving exposed skin areas. Rapid, effective treatment of AD across body regions remains an unmet need, particularly for difficult-to-treat areas such as the head and neck area. We investigated...
Autores principales: | Alexis, Andrew, de Bruin-Weller, Marjolein, Weidinger, Stephan, Soong, Weily, Barbarot, Sebastien, Ionita, Ileana, Zhang, Fan, Valdez, Hernan, Clibborn, Claire, Yin, Natalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940992/ https://www.ncbi.nlm.nih.gov/pubmed/35297025 http://dx.doi.org/10.1007/s13555-022-00694-1 |
Ejemplares similares
-
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021) -
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021) -
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023) -
Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021) -
Early Itch Response with Abrocitinib Is
Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic
Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE
Trial
por: Ständer, Sonja, et al.
Publicado: (2022)